INCLINE VILLAGE, Nev.,
Feb. 22, 2017 /PRNewswire/
-- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI)
today announced that the Company will release its fourth quarter,
year-end 2016 financial results for the period ended December 31, 2016, on Wednesday, March 1, 2017, after market close.
PDL's management will host a conference call and webcast that day
at 4:30 p.m. Eastern Time to discuss
the financial results. A slide presentation relating to the call
will be available via the webcast link on the PDL website.
Conference Call Details
To access the live conference call via phone, please dial (800)
668-4132 from the United States
and Canada or (224) 357-2196
internationally. The conference ID is 77416821. Please dial in
approximately 10 minutes prior to the start of the call. A
telephone replay will be available for one week following the call
and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The
replay passcode is 77416821.
To access the live and subsequently archived webcast of the
conference call, go to the Company's website at http://www.pdl.com
and go to "Events & Presentations." Please connect to the
website at least 15 minutes prior to the call to allow for any
software download that may be necessary.
About PDL BioPharma
PDL seeks to provide a significant return for its shareholders by
acquiring and managing a portfolio of companies, products, royalty
agreements and debt facilities in the biotech, pharmaceutical and
medical device industries. In late 2012, PDL began providing
alternative sources of capital through royalty monetizations and
debt facilities and in 2016, began making equity investments in
commercial stage companies, the first being Noden Pharma DAC.
PDL has committed over $1.4 billion
and funded approximately $1.1 billion
in these investments to date.
PDL was formerly known as Protein Design Labs, Inc. and changed
its name to PDL BioPharma, Inc. in 2006. PDL was founded in
1986 and is headquartered in Incline
Village, Nevada. PDL pioneered the humanization of
monoclonal antibodies and, by doing so, enabled the discovery of a
new generation of targeted treatments for cancer and immunologic
diseases for which it has received significant royalty revenue.
NOTE: PDL BioPharma and the PDL BioPharma logo are
considered trademarks of PDL BioPharma, Inc.
Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/pdl-biopharma-to-announce-fourth-quarter--year-end-2016-financial-results-on-march-1-2017-300411387.html
SOURCE PDL BioPharma, Inc.